Pfizer’s Vydura (rimegepant) Receives the NICE Recommendation for the Prevention of Migraine Attacks
- NICE issued the draft guidance recommending rimegepant for preventive use on the NHS in England to prevent migraines in adults who have at least four and fewer than 15 migraine attacks a month
- The clinical trial evidence showed that rimegepant works better than other treatments for reducing the number of episodic migraines in patients
- NICE is expected to publish final guidance on rimegepant for preventing episodic migraines in the next month. Additionally, NICE recommended erenumab, fremanezumab or galcanezumab are antibody proteins engineered to target and neutralize other proteins or their receptors
Ref: Nice | Image: Pfizer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.